Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | GAPDH | P04406 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30914726 | 0.78 | ACHE (0.43) | ACHEBACE1HCAR2ATMMAPT | |
| SCHEMBL7870030 | 0.77 | ACHE (0.56) | ACHEBACE1MAPTOXER1TRPA1 | |
| SCHEMBL7870031 | 0.77 | ACHE (0.56) | ACHEBACE1MAPTOXER1TRPA1 | |
| SCHEMBL16656923 | 0.75 | ACHE (0.37) | ACHEBACE1HCAR2ATMTSHR | |
| SCHEMBL17828265 | 0.74 | HCAR2 (0.52) | HCAR2ATMTSHRMAPT | |
| SCHEMBL34468187 | 0.72 | HCAR2 (0.46) | HCAR2ATMMAPT | |
| SCHEMBL22627138 | 0.72 | HCAR2 (0.46) | HCAR2ATMTSHRMAPTTRPA1 | |
| SCHEMBL22465645 | 0.72 | HCAR2 (0.46) | HCAR2ATMTSHRMAPTTRPA1 | |
| SCHEMBL7017427 | 0.71 | MAPT (0.53) | TSHRMAPT | |
| SCHEMBL18723218 | 0.71 | HCAR2 (0.45) | HCAR2ATMMAPTGPR84ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102650-B2 | Synthesis of new anti-inflammatory compound | XU YONG (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150112087-A1 | Synthesis of New Anti-Inflammatory Compound | XU YONG (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112087-A1 | Synthesis of New Anti-Inflammatory Compound | TNF, PTGES2, RELA | ACHE 245/4885BACE1 1007/4885HCAR2 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.